Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology

Abstract

NTX is FDA-approved for opiate and alcohol use disorders as anti-craving agent. It has been used successfully off-label in other psychiatric indications. Here, we shed some light on these while examining the extant evidence.

Keywords

binge eating, naltrexone, obesity, paraphilia, pathologic gambling, SIBs, SUDs

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Not yet subscribed? View subscription options

Purchase Article

Buy single-article access with a one-time purchase.

$30.00

Add to Cart

How to Cite

Ahmed Naguy, Bibi Alamiri. Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology. Psychopharmacology Bulletin. 2024/07/08; 54(3):97-99. https://doi.org/10.64719/pb.4496